Of the tracked stories, 12 of 20 also mention SpaceX, the most common co-covered peer. The 154-day window averages about 0.9 stories each week. The busiest single day carried 3. The clearest coverage concentration is markets: 5 of 20 stories, with the rest divided among 8 other categories.
Coverage balanceBalanced directional read. Positive and negative coverage are within 5 percentage points.
35% positive
35% neutral
30% negative
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Rocket Lab
Of the tracked stories, 12 of 20 also mention SpaceX, the most common co-covered peer. The 154-day window averages about 0.9 stories each week. The busiest single day carried 3. The clearest coverage concentration is markets: 5 of 20 stories, with the rest divided among 8 other categories. We currently track 20 Cross-Sector stories that mention Rocket Lab, published between March 19, 2026 and August 19, 2026. 30% of these stories carry negative sentiment. The tracked stories average 2.8 original sources each.
Stories tracked
20
Per week
0.9
Negative
30%
Sources per story
2.8
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Rocket Lab. Shared-story counts are live from our verified record — not editorial picks.
Rocket Lab's $397 million U.S. Space Force award for stackable Flatellite satellite buses positions the company as a vertically integrated prime for the SB-AMTI missile-tracking constellation. The deal validates years of component acquisitions and Neutron's mass-launch role, intensifying pressure on incumbent defense primes.
Viasat has named Rocket Lab to manufacture a geostationary satellite for the U.S. Space Force's Protected Tactical SATCOM-Global program, a key step toward fielding anti-jam tactical communications. The selection validates Rocket Lab's spacecraft manufacturing ambitions beyond its small-satellite heritage.
Rocket Lab's new GHOST containerized launch system turns Electron and HASTE rockets into a tactically responsive, launch-anywhere capability. With 83 Electron missions and 9 HASTE flights already completed, GHOST aims to capture growing defense and commercial demand for rapid space access, while expanding the company's global footprint beyond existing pads in New Zealand, Virginia, and soon Alaska.
Investors eyeing the space economy face a clear risk/reward calculus. SpaceX, accessible via SPCX, has a self-funding Starlink business and massive optionality, while Rocket Lab (RKLB) remains unprofitable and dependent on the Neutron rocket's success. Both stocks moved sharply on the comparison, underscoring market sentiment.
A MarketBeat screener on July 18, 2026, highlighted 7 defense and 5 entertainment stocks with the highest dollar trading volume, reflecting a market balancing geopolitical risks and consumer trends. Lockheed Martin and Disney were among the notable names.
Metaverse stocks saw high dollar trading volume on July 18, coinciding with Bitcoin’s rise above $98,500. The screen included Global Mofy AI and HUB Cyber Security, suggesting renewed appetite for Web3-adjacent assets among crypto-focused investors.
Rocket Lab's $8 billion acquisition of Iridium merges launch and satellite manufacturing with a global L-band constellation, creating an integrated space platform. The deal secures irreplicable spectrum and aviation PNT services, reshaping the defense and telecom landscape by 2027.
Retail investors who poured over $300 million into SpaceX’s IPO frenzy abruptly pulled back, with net buys plunging to $9.1M. The reversal poses fresh questions about the sustainability of high-flying valuations for space startups and the IPO window for venture-backed rivals.
SpaceX's 6.5% plunge on June 18 vaporized over $150 billion in market cap, triggering a sector-wide rout that hit Rocket Lab, AST SpaceMobile, and other key space players. The correction tests the resilience of the commercial space supply chain and defense contractors tied to Elon Musk’s ecosystem.
The largest IPO in history hit its first major air pocket as investors booked profits, sending SpaceX shares down 6.5% and erasing over $150 billion in market value. The retreat highlights structural risks from thin float and outsized retail influence in mega-listings.
SpaceX’s move to public markets marks a watershed for space startups, creating a valuation benchmark and a clear exit path. With Rocket Lab generating $200.3M in quarterly revenue and targeting a medium-lift rocket, private launch companies are recalibrating their funding strategies.
As SpaceX finally goes public, the commercial launch sector gets a benchmark. Rocket Lab’s record $200.3M quarterly revenue and the upcoming Neutron rocket position it as the leading public proxy. This shift is resetting competitive dynamics for the entire space industry.
SpaceX’s public listing under SPCX is giving Wall Street its first reference price for the launch economy. Rocket Lab, with record $200.3M quarterly revenue and a $2.2B backlog, is the most direct liquid proxy—but the repricing of space stocks is just beginning.
SpaceX's record IPO is cooling fast despite a $60B all-stock acquisition of AI startup Anysphere, signaling volatility that could reset exit expectations for unicorns.
Rocket Lab (RKLB) has recorded a 238% stock price increase over the past year, driven by a record launch cadence and the rapid development of its medium-lift Neutron rocket. The company is successfully transitioning from a niche small-satellite launcher into a vertically integrated space systems powerhouse, positioning it as the primary public-market alternative to SpaceX.
A significant wave of analyst rating changes has hit the market, featuring a notable downgrade for boutique fitness giant Xponential Fitness and a bullish initiation for space leader Rocket Lab. These shifts underscore a broader institutional reassessment of growth trajectories across the fitness, aerospace, and biotechnology sectors.
Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Apogee Therapeutics and Arcturus Therapeutics faced simultaneous downgrades and initiations in a single trading session, highlighting a sharp divide in analyst sentiment. This volatility reflects broader market uncertainty regarding clinical-stage biotech valuations and the specific pipelines of these immunology and mRNA specialists.